CAR T-Cell Therapy Achieves Lasting Remission in Multiple Myeloma | |
Recent clinical trials have demonstrated unprecedented advances in the treatment of multiple myeloma with CAR T-cell therapy. This novel approach involves genetically modifying a patient's T-cells to be more effective at targeting and killing myeloma cells, promising long-term remission. FOR MORE INFORMATION CLICK HERE ➖ https://www.edhacare.com/treatments/cancer/car-t-cell-therapy Multiple myeloma is a cancer of the plasma cells that has been hard to treat traditionally, with relapses often occurring after standard therapies. CAR T-cell therapy, however, has shown a marked decrease in the populations of cancerous cells, and patients have entered into long periods of remission. Early-phase trials have shown the potential for this treatment to increase survival rates and improve the quality of life for patients. This involves extracting T-cells from the patient, modifying them to target myeloma cells, and reintroducing these engineered cells back into the patient. It focuses on antigens unique to myeloma cells; hence, modified T-cells will eliminate cancer with greater ease. CAR T-cell therapy has become one of the greatest developments in multiple myeloma management as it could result in lasting remission for the patients. | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: All States Target City : All Cities Last Update : Jan 24, 2025 4:17 AM Number of Views: 54 | Item Owner : JOHNSHON Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |